[go: up one dir, main page]

RU2000124084A - Chimeric antibody that binds to human CD40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treating a T-cell mediated disease (variants), method for treating a patient for a disease mediated by T cells (options) - Google Patents

Chimeric antibody that binds to human CD40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treating a T-cell mediated disease (variants), method for treating a patient for a disease mediated by T cells (options)

Info

Publication number
RU2000124084A
RU2000124084A RU2000124084/13A RU2000124084A RU2000124084A RU 2000124084 A RU2000124084 A RU 2000124084A RU 2000124084/13 A RU2000124084/13 A RU 2000124084/13A RU 2000124084 A RU2000124084 A RU 2000124084A RU 2000124084 A RU2000124084 A RU 2000124084A
Authority
RU
Russia
Prior art keywords
variable region
variants
seq
heavy chain
sequence
Prior art date
Application number
RU2000124084/13A
Other languages
Russian (ru)
Other versions
RU2220980C2 (en
Inventor
Алехандро А. АРАФФО
Диан ХОЛЛЕНБОГ
Энтони В. СИАДЭК
Карен К. БЕРРИ
Линда Дж. ХАРРИС
Барбара А. ТОРН
Юрген БАЖОРАТ
Уильям Д. ХЬЮЗ
Херрен ВУ
Джефри Д. УОТКИНС
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/026,291 external-priority patent/US6051228A/en
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of RU2000124084A publication Critical patent/RU2000124084A/en
Application granted granted Critical
Publication of RU2220980C2 publication Critical patent/RU2220980C2/en

Links

Claims (30)

1. Вариабельный участок легкой цепи, содержащий полную аминокислотную последовательность SEQ ID NO:l (Фиг. 4а), или его биологически активный фрагмент.1. The variable region of the light chain containing the complete amino acid sequence of SEQ ID NO: l (Fig. 4A), or a biologically active fragment thereof. 2. Вариабельный участок тяжелой цепи, содержащий полную аминокислотную последовательность SEQ ID NO:2 (Фиг. 4b), или его биологически активный фрагмент.2. The variable region of the heavy chain containing the complete amino acid sequence of SEQ ID NO: 2 (Fig. 4b), or a biologically active fragment thereof. 3. Химерное антитело, которое связывается с CD40 человека, содержащее легкую и тяжелую цепь, причем указанная легкая цепь содержит вариабельный участок по п. 1.3. A chimeric antibody that binds to human CD40 containing a light and heavy chain, said light chain comprising a variable region according to claim 1. 4. Химерное антитело, которое связывается с CD40 человека, содержащее легкую и тяжелую цепь, причем указанная тяжелая цепь содержит вариабельный участок по п. 2.4. A chimeric antibody that binds to human CD40 containing a light and a heavy chain, said heavy chain comprising a variable region according to claim 2. 5. Химерное антитело по п. 3, отличающееся тем, что указанная тяжелая цепь содержит вариабельный участок по п. 2.5. Chimeric antibody according to claim 3, characterized in that said heavy chain contains a variable region according to claim 2. 6. Химерное антитело, которое связывается с CD40 человека, содержащее легкую и тяжелую цепь, причем указанная легкая цепь содержит полную аминокислотную последовательность SEQ ID NO:4 или ее биологически активный фрагмент, а указанная тяжелая цепь содержит полную аминокислотную последовательность SEQ ID NO:3 или ее биологически активный фрагмент.6. A chimeric antibody that binds to human CD40 containing a light and heavy chain, said light chain containing the complete amino acid sequence of SEQ ID NO: 4 or a biologically active fragment thereof, and said heavy chain containing the complete amino acid sequence of SEQ ID NO: 3 or its biologically active fragment. 7. Молекула нуклеиновой кислоты, представляющая собой нуклеотидную последовательность, кодирующую вариабельный участок легкой цепи по п. 1.7. A nucleic acid molecule, which is a nucleotide sequence encoding a variable region of the light chain according to claim 1. 8. Молекула нуклеиновой кислоты, представляющая собой нуклеотидную последовательность, кодирующую вариабельный участок тяжелой цепи по п. 2.8. The nucleic acid molecule, which is a nucleotide sequence encoding the variable region of the heavy chain according to claim 2. 9. Вектор экспрессии, содержащий последовательность нуклеиновой кислоты по п. 7.9. An expression vector containing the nucleic acid sequence of claim 7. 10. Вектор экспрессии, содержащий последовательность нуклеиновой кислоты по п. 8.10. An expression vector containing the nucleic acid sequence of claim 8. 11. Гуманизированное антитело, содержащее фрагмент вариабельного участка легкой цепи по п. 1.11. Humanitariannet antibody containing a fragment of the variable region of the light chain according to claim 1. 12. Гуманизированное антитело, содержащее фрагмент вариабельного участка тяжелой цепи по п. 2.12. Humanitariannet antibody containing a fragment of the variable region of the heavy chain according to claim 2. 13. Фармацевтическая композиция, содержащая химерное антитело по п. 5.13. A pharmaceutical composition comprising a chimeric antibody according to claim 5. 14. Фармацевтическая композиция, содержащая химерное антитело по п. 6.14. A pharmaceutical composition comprising a chimeric antibody according to claim 6. 15. Химерное антитело, которое связывается с CD40 человека, содержащее вариабельный участок легкой цепи и вариабельный участок тяжелой цепи, причем указанный вариабельный участок легкой цепи имеет аминокислотную последовательность, по крайней мере, на 90% идентичную последовательности вариабельного участка легкой цепи по п. 1.15. A chimeric antibody that binds to human CD40 comprising a light chain variable region and a heavy chain variable region, wherein said light chain variable region has an amino acid sequence that is at least 90% identical to the sequence of the light chain variable region of claim 1. 16. Химерное антитело, которое связывается с CD40 человека, содержащее вариабельный участок легкой цепи и вариабельный участок тяжелой цепи, причем указанный вариабельный участок тяжелой цепи имеет аминокислотную последовательность, по крайней мере, на 90% идентичную последовательности вариабельного участка тяжелой цепи по п. 2.16. A chimeric antibody that binds to human CD40 comprising a light chain variable region and a heavy chain variable region, said variable heavy chain region having an amino acid sequence that is at least 90% identical to the sequence of the variable region of the heavy chain according to claim 2. 17. Способ лечения больного, страдающего от заболевания, опосредованного Т-клетками, предусматривающий введение указанному больному терапевтически эффективной дозы фармацевтической композиции по п. 14.17. A method of treating a patient suffering from a T-cell mediated disease, comprising administering to said patient a therapeutically effective dose of a pharmaceutical composition according to claim 14. 18. Молекула нуклеиновой кислоты по п. 7, имеющая последовательность нуклеотидов SEQ ID NO:6.18. The nucleic acid molecule according to claim 7, having the nucleotide sequence of SEQ ID NO: 6. 19. Молекула нуклеиновой кислоты по п. 8, имеющая последовательность нуклеотидов SEQ ID NO:5.19. The nucleic acid molecule according to claim 8, having the nucleotide sequence of SEQ ID NO: 5. 20. Химерное антитело по п. 6, содержащее легкую цепь с аминокислотной последовательностью SEQ ID NO:4 и тяжелую цепь с аминокислотной последовательностью SEQ ID NO:3.20. The chimeric antibody according to claim 6, containing a light chain with the amino acid sequence of SEQ ID NO: 4 and a heavy chain with the amino acid sequence of SEQ ID NO: 3. 21. Гуманизированное антитело по п. 11, содержащее вариабельный участок легкой цепи с последовательностью SEQ ID NO:8.21. The humanized antibody according to claim 11, containing the variable region of the light chain with the sequence of SEQ ID NO: 8. 22. Гуманизированное антитело по п. 11, содержащее вариабельный участок тяжелой цепи с последовательностью SEQ ID NO:10.22. The humanized antibody according to claim 11, containing the variable region of the heavy chain with the sequence of SEQ ID NO: 10. 23. Гуманизированное антитело по п. 12, содержащее вариабельный участок легкой цепи с последовательностью SEQ ID NO:8.23. The humanized antibody according to claim 12, containing the variable region of the light chain with the sequence of SEQ ID NO: 8. 24. Гуманизированное антитело по п. 12, содержащее вариабельный участок тяжелой цепи с последовательностью SEQ ID NO:10.24. The humanized antibody according to claim 12, containing the variable region of the heavy chain with the sequence of SEQ ID NO: 10. 25. Гуманизированное антитело по п. 11, содержащее вариабельный участок легкой цепи с последовательностью SEQ ID NO:8 и вариабельный участок тяжелой цепи с последовательностью SEQ ID NO:10.25. The humanized antibody of claim 11, comprising the variable region of the light chain with the sequence of SEQ ID NO: 8 and the variable region of the heavy chain with the sequence of SEQ ID NO: 10. 26. Гуманизированное антитело по п. 11, содержащее вариабельный участок легкой цепи с последовательностью SEQ ID NO:12.26. The humanized antibody of claim 11, comprising the variable region of the light chain with the sequence of SEQ ID NO: 12. 27. Гуманизированное антитело по п. 26, содержащее вариабельный участок тяжелой цепи с последовательностью SEQ ID NO:10.27. The humanized antibody of claim 26, comprising the variable region of the heavy chain with the sequence of SEQ ID NO: 10. 28. Гуманизированное антитело по п. 11, содержащее вариабельный участок легкой цепи с последовательностью SEQ ID NO:12 и вариабельный участок тяжелой цепи с последовательностью SEQ ID NO:10.28. The humanized antibody of claim 11, comprising the variable region of the light chain with the sequence of SEQ ID NO: 12 and the variable region of the heavy chain with the sequence of SEQ ID NO: 10. 29. Фармацевтическая композиция, содержащая гуманизированное антитело по п. 25.29. A pharmaceutical composition comprising the humanized antibody of claim 25. 30. Фармацевтическая композиция, содержащая гуманизированное антитело по п.28.30. A pharmaceutical composition comprising the humanized antibody of claim 28.
RU2000124084/13A 1998-02-19 1999-02-10 Chimeric antibody that binds with human cd40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treatment of disease mediated by t-cells (variants), method for treatment of patient with diseases mediated by t-cells (variants) RU2220980C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/026,291 1998-02-19
US09/026,291 US6051228A (en) 1998-02-19 1998-02-19 Antibodies against human CD40

Publications (2)

Publication Number Publication Date
RU2000124084A true RU2000124084A (en) 2003-11-10
RU2220980C2 RU2220980C2 (en) 2004-01-10

Family

ID=21830976

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000124084/13A RU2220980C2 (en) 1998-02-19 1999-02-10 Chimeric antibody that binds with human cd40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treatment of disease mediated by t-cells (variants), method for treatment of patient with diseases mediated by t-cells (variants)

Country Status (31)

Country Link
US (3) US6051228A (en)
EP (1) EP1054692A4 (en)
JP (1) JP2002503495A (en)
KR (1) KR100564376B1 (en)
CN (1) CN1198647C (en)
AR (1) AR018101A1 (en)
AU (1) AU751064B2 (en)
BG (1) BG65010B1 (en)
BR (1) BR9908045A (en)
CA (1) CA2321165A1 (en)
CO (1) CO4830493A1 (en)
CZ (1) CZ20003008A3 (en)
EE (1) EE200000470A (en)
GE (1) GEP20033016B (en)
HU (1) HUP0100763A3 (en)
ID (1) ID25792A (en)
IL (2) IL137294A0 (en)
LT (1) LT4837B (en)
LV (1) LV12561B (en)
MY (1) MY121464A (en)
NO (1) NO20004133L (en)
NZ (1) NZ505696A (en)
PE (1) PE20000268A1 (en)
PL (1) PL197143B1 (en)
RU (1) RU2220980C2 (en)
SK (1) SK12092000A3 (en)
TR (1) TR200002405T2 (en)
TW (1) TWI226334B (en)
UA (1) UA71909C2 (en)
WO (1) WO1999042075A2 (en)
ZA (1) ZA991307B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288251B2 (en) 2001-11-09 2007-10-30 Abgenix, Inc. Antibodies to CD40

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US7175847B1 (en) * 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7153508B2 (en) * 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
WO1998003670A1 (en) * 1996-07-23 1998-01-29 Tanox Pharma B.V. Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
EP2039368A3 (en) 1999-04-30 2009-04-01 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
NZ514914A (en) * 1999-05-07 2004-09-24 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US7074403B1 (en) * 1999-06-09 2006-07-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2001013945A1 (en) * 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
EP1839674A1 (en) * 1999-10-04 2007-10-03 Novartis Vaccines and Diagnostics, Inc. CD40 antagonist for treating psoriasis
AU1072701A (en) * 1999-10-04 2001-05-10 Chiron Corporation Cd40 antagonist for treating psoriasis
US6849425B1 (en) * 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
WO2001034649A2 (en) * 1999-11-09 2001-05-17 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
GB0006398D0 (en) * 2000-03-16 2000-05-03 Novartis Ag Organic compounds
WO2002011763A1 (en) * 2000-04-19 2002-02-14 Tanox, Inc. Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
CA2422076A1 (en) * 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
IL157946A0 (en) * 2001-04-02 2004-03-28 Genentech Inc Combination therapy
CN101508734A (en) * 2001-04-27 2009-08-19 协和发酵麒麟株式会社 Anti-CD40 monoclonal antibody
WO2003024480A2 (en) * 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
JP2005510570A (en) * 2001-11-26 2005-04-21 カイロン コーポレイション Antagonist anti-CD40 monoclonal antibody therapy for treatment of multiple sclerosis
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
DE60333732D1 (en) * 2002-03-01 2010-09-23 Immunomedics Inc INTERNALIZATION OF ANTI CD74 MONOCLONAL ANTIBODIES AND THEIR USES
AU2003300842A1 (en) * 2002-12-09 2004-06-30 Tolerrx, Inc. Inducing tolerance in primates
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
RS53073B (en) * 2003-11-04 2014-04-30 Novartis Vaccines And Diagnostics Inc. Use of antagonistic anti-cd40 monoclonal antibodies
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US20110171126A1 (en) * 2010-01-11 2011-07-14 Center For Molecular Medicine And Immunology Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-Gamma
CN1980957A (en) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 Receptor coupling agents and therapeutic uses thereof
WO2006046935A1 (en) * 2004-10-22 2006-05-04 Applied Molecular Evolution, Inc Methods of optimizing antibody variable region binding affinity
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
DK1868635T3 (en) * 2005-04-06 2017-09-11 Bristol Myers Squibb Co METHODS OF TREATING IMMUNE DISEASES IN CONNECTION WITH ORGAN TRANSPLANTATION WITH SOLUBLE, Mutating CTLA4 MOLECULES
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
PT1889065E (en) * 2005-05-18 2013-09-27 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
PL1885399T3 (en) * 2005-05-26 2011-04-29 Seattle Genetics Inc Humanized anti-cd40 antibodies and their methods of use
US7668387B2 (en) * 2005-06-20 2010-02-23 Intel Corporation Selective local transient improvement and peaking for video sharpness enhancement
PT1912675E (en) * 2005-07-25 2014-05-09 Emergent Product Dev Seattle B-cell reduction using cd37-specific and cd20-specific binding molecules
US20080131914A1 (en) * 2005-09-14 2008-06-05 Ahearn Joseph M Assessing risk of cerebrovascular thrombosis by measuring c4d
US20070202549A1 (en) * 2005-09-14 2007-08-30 University Of Pittsburgh Assessing risk of cerebrovascular thrombosis by measuring C4d on platelets
WO2007033369A2 (en) * 2005-09-14 2007-03-22 University Of Pittsburgh Assessing risk of cerebrovascular thrombosis by measuring c4d on platelets
KR20080073725A (en) 2005-11-01 2008-08-11 노파르티스 아게 Use of anti-CD40 antibodies
MX2008013508A (en) 2006-04-21 2008-10-31 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions.
AU2007248628B2 (en) * 2006-05-03 2013-02-07 The Regents Of The University Of Colorado, A Body Corporate CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
EP1854810A1 (en) * 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
AU2007281737B2 (en) * 2006-08-04 2013-09-19 Baxter Healthcare S.A. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
BRPI0813514A2 (en) * 2007-07-16 2019-09-24 Genentech Inc humanized and immunoconjugated anti-cd79b antibodies and methods of use
EP2657253B1 (en) 2008-01-31 2017-07-19 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
WO2010104749A2 (en) 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
DK3138854T3 (en) * 2009-03-10 2022-04-11 Baylor Res Institute Antibodies to CD40
MA34091B1 (en) 2010-03-31 2013-03-05 Boehringer Ingelheim Int Antibody antibody cd40
DK2569013T3 (en) * 2010-05-14 2017-02-13 Univ Leland Stanford Junior HUMANIZED AND CHEMICAL MONOCLONAL ANTIBODIES FOR CD47
AR083847A1 (en) 2010-11-15 2013-03-27 Novartis Ag FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES
EP2683406B1 (en) 2011-03-11 2019-05-08 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
LT2699601T (en) 2011-04-21 2018-03-26 Bristol-Myers Squibb Company Antibody polypeptides that antagonize cd40
RU2609647C2 (en) 2011-04-29 2017-02-02 Апексиджен, Инк. Anti-cd40-antibodies and methods of application
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
SMT202000091T1 (en) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Antibody polypeptides that antagonize cd40l
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
CA2853138A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
CN109265552A (en) 2012-10-30 2019-01-25 埃派斯进有限公司 Anti-CD 40 antibodies and its application method
ES2819573T3 (en) 2012-12-13 2021-04-16 Immunomedics Inc Method for Producing Antibody-SN-38 Immunoconjugates with a CL2A Linker
CA2884313C (en) 2012-12-13 2023-01-03 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US20240139324A1 (en) 2012-12-13 2024-05-02 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP3094652B1 (en) 2014-01-13 2021-09-29 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
DK3180087T3 (en) 2014-08-12 2019-05-13 Alligator Bioscience Ab COMBINATION THERAPIES WITH ANTI CD40 ANTIBODIES
SG11201702056YA (en) * 2014-09-16 2017-04-27 United Biomedical Inc Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition
PT3262071T (en) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Method of using anti-cd79b immunoconjugates
KR20240073140A (en) 2014-10-29 2024-05-24 씨젠 인크. Dosage and administration of non-fucosylated anti-cd40 antibodies
US9888673B2 (en) 2014-12-10 2018-02-13 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
EP3286224A4 (en) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
HUE048284T2 (en) 2015-05-29 2020-07-28 Abbvie Inc Anti-CD40 antibodies and their use
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
SI3307322T1 (en) 2015-09-04 2021-08-31 Primatope Therapeutics Inc. Humanized antibodies to CD40 and their uses
EP3355921A4 (en) 2015-09-30 2019-05-22 Janssen Biotech, Inc. Antagonistic antibodies specifically binding human cd40 and methods of use
WO2017139623A1 (en) 2016-02-10 2017-08-17 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
US10266605B2 (en) 2016-04-27 2019-04-23 Immunomedics, Inc. Efficacy of anti-trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
JP7261379B2 (en) 2016-06-20 2023-04-20 カイマブ・リミテッド Anti-PD-L1 antibody
EP3600283A4 (en) 2017-03-27 2020-12-16 Immunomedics, Inc. Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
WO2020014974A1 (en) 2018-07-20 2020-01-23 Eucure (Beijing) Biopharma Co., Ltd Anti-cd40 antibodies and uses thereof
US20200190163A1 (en) * 2018-10-26 2020-06-18 Lijun Wu Humanized bcma-car-t cells
CN113166246B (en) * 2018-12-28 2024-10-18 四川科伦博泰生物医药股份有限公司 Antibody and application thereof
CN111454364B (en) * 2019-03-04 2021-03-02 北京天广实生物技术股份有限公司 Antibodies that bind CD40 and uses thereof
US20220348650A1 (en) * 2019-09-03 2022-11-03 Bio-Thera Solutions, Ltd. Anti-tigit immunosuppressant and application thereof
CN113563473A (en) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 Tetravalent bispecific antibody, preparation method and application thereof
CN111763259B (en) * 2020-09-03 2020-12-15 北京百奥赛图基因生物技术有限公司 anti-CD 40 antibodies and uses thereof
US20250002527A1 (en) 2021-08-26 2025-01-02 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
CN118234749A (en) * 2021-09-17 2024-06-21 诺华股份有限公司 Method for preventing graft rejection in xenografts
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
US20240190978A1 (en) 2022-11-15 2024-06-13 CSBioAsset LLC Compositions and methods for immunomodulatory bifunctional fusion molecules

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1993011252A1 (en) * 1991-11-26 1993-06-10 The Regents Of The University Of California Cloning vectors for expressing pcr generated variable regions as complete heavy and/or light chain(s)
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
ES2185770T3 (en) * 1995-04-08 2003-05-01 Lg Chemical Ltd SPECIFIC MONOCLONAL ANTIBODY FOR 4-1BB HUMAN AND CELL LINE THAT PRODUCES IT.
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
KR20000034847A (en) * 1998-11-17 2000-06-26 성재갑 Humanized Antibody Specific for Human 4-1BB Molecule and Pharmaceutical Composition Comprising Same

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288251B2 (en) 2001-11-09 2007-10-30 Abgenix, Inc. Antibodies to CD40
US7338660B2 (en) 2001-11-09 2008-03-04 Abgenix, Inc. Methods of treating cancer and enhancing immune responses with antibodies that bind CD40
US7563442B2 (en) 2001-11-09 2009-07-21 Abgenix, Inc. Antibodies to CD40 and methods of treating cancer and enhancing immune responses
US7618633B2 (en) 2001-11-09 2009-11-17 Amgen Fremont Inc. Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses
US7626012B2 (en) 2001-11-09 2009-12-01 Amgen Fremont Inc. Nucleic acid molecules which encode antibodies that bind CD40
US8388971B2 (en) 2001-11-09 2013-03-05 Amgen Fremont Inc. Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses

Similar Documents

Publication Publication Date Title
RU2000124084A (en) Chimeric antibody that binds to human CD40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treating a T-cell mediated disease (variants), method for treating a patient for a disease mediated by T cells (options)
RU2220980C2 (en) Chimeric antibody that binds with human cd40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treatment of disease mediated by t-cells (variants), method for treatment of patient with diseases mediated by t-cells (variants)
RU2207878C2 (en) "humanized" antibodies raised against human gp39, compositions comprising these antibodies and their therapeutic using
RU2421464C2 (en) Human il-13 antibodies and their therapeutic application
KR920002315B1 (en) Complementary polypeptides for proteins or peptides whose at least a portion of a nucleotide code sequence or amino acid sequence is known and methods of designing the same
RU2432364C2 (en) POLYCLONAL Nogo ANTIBODY, PHARMACEUTICAL COMPOSITION AND APPLICATION OF ANTIBODY FOR PREPARING DRUG
RU2006115835A (en) HUMAN ANTIBODIES AGAINST HUMAN 4-1BB (CD137)
DK1032671T3 (en) Mammalian cytokine-like polypeptide-10
RU2000109255A (en) "HUMANIZED" ANTIBODIES AGAINST HUMAN GP39, COMPOSITIONS CONTAINING THESE ANTIBODIES AND THEIR THERAPEUTIC USES
IL212686A (en) Oligodendrocyte binding human monoclonal igm antibodies and compositions and uses thereof
CA2189015A1 (en) Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases
RU2009149294A (en) ANTIGEN BINDING PROTEINS AIMED AT ORF0657N S.AUREUS
EA200901129A1 (en) NUCLEIC ACIDS AND POLYPEPTIDES OF THE NEW RECEPTOR
RU2006101149A (en) RECOMBINANT ADENO-ASSOCIATED VIRAL VECTOR FOR TREATMENT OF ALZHEIMER'S DISEASE
WO1995021919A3 (en) Protein having tpo activity
RU98120519A (en) AUTOANTIGEN AND STRUCTURAL-RELATED PROTEINS FOR USE IN IMMUNOTHERAPY OF AUTOIMMUNE DISEASES
RU97105374A (en) MODIFIED PROTEINS
CN114829395A (en) anti-ANGPTL 3 antibodies and uses thereof
RU2001132140A (en) Recombinant platelet collagen receptor glycoprotein VI and its use in pharmaceuticals
JP2009524428A5 (en)
CA2370098A1 (en) Human beta-trcp protein
ATE310828T1 (en) IMPLANT AND VECTOR FOR THE TREATMENT OF ACQUIRED DISEASES
WO2004110355A3 (en) Compositions and methods including a recombinant human mab that promotes cns remyelination
RU2003129163A (en) POLINUCLEOTID, WHICH CAN BE USED TO MODULATE CANCER CELL PROLIFERATION
RU97104072A (en) BODY WEIGHT MODULATORS ACCORDING TO NUCLEIC ACIDS AND PROTEINS, AND ALSO THEIR APPLICATION FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES